Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis
Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis
复制标题
Xpert MTB/RIF 检测用于诊断不同地区利福平耐药性：荟萃分析
DOI：
10.1186/s12866-019-1516-5
复制
发表时间：
2019-08-05
期刊：
影响因子：
4.2
通讯作者：
Li，Shiying
中科院分区：
文献类型：
--
作者：
Zong，Kaican;Luo，Chen;Li，Shiying
背景为评估Xpert MTB/RIF对不同地区利福平耐药的诊断准确性，进行荟萃分析。方法检索多个数据库截至2019年3月3日的相关研究，采用双变量随机效应模型评估诊断准确性。结果我们筛选出97项研究，涉及26,037个样本，用于诊断利福平耐药。 Xpert MTB/RIF 检测利福平耐药性的汇总敏感性、特异性和 AUC 分别为 0.93 (95% CI 0.90–0.95)、0.98 (95% CI 0.96–0.98) 和 0.99 (95% CI 0.97–0.99)。对于不同区域，汇总敏感性分别为 0.94（95% CI 0.89–0.97）和 0.92（95% CI 0.88–0.94），汇总特异性分别为 0.98（95% CI 0.94–1.00）和 0.98（95% CI 0.96–0.99），AUC 为 0.99（95% CI 0.96–0.99）。高收入和中/低收入国家的 CI 分别为 0.98–1.00) 和 0.99 (95% CI 0.97–0.99)。合并敏感性为 0.91 (95% CI 0.87–0.94) 和 0.91 (95% CI 0.86–0.94)，合并特异性为 0.98 (95% CI 0.96–0.99) 和 0.98 (95% CI 0.96–0.99)，AUC 为 0.98 (95% CI 0.96–0.99)。在结核病高负担国家和中/低流行国家中分别为 0.97–0.99) 和 0.99 (95% CI 0.97–0.99)。结论 Xpert MTB/RIF 对利福平耐药性检测的诊断准确性非常好。
BackgroundTo estimate the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance in different regions, a meta-analysis was carried out.MethodsSeveral databases were searched for relevant studies up to March 3, 2019. A bivariate random-effects model was used to estimate the diagnostic accuracy.ResultsWe identified 97 studies involving 26,037 samples for the diagnosis of rifampicin resistance. The pooled sensitivity, specificity and AUC of Xpert MTB/RIF for rifampicin resistance detection were 0.93 (95% CI 0.90–0.95), 0.98 (95% CI 0.96–0.98) and 0.99 (95% CI 0.97–0.99), respectively. For different regions, the pooled sensitivity were 0.94(95% CI 0.89–0.97) and 0.92 (95% CI 0.88–0.94), the pooled specificity were 0.98 (95% CI 0.94–1.00) and 0.98 (95% CI 0.96–0.99), and the AUC were 0.99 (95% CI 0.98–1.00) and 0.99 (95% CI 0.97–0.99) in high and middle/low income countries, respectively. The pooled sensitivity were 0.91 (95% CI 0.87–0.94) and 0.91 (95% CI 0.86–0.94), the pooled specificity were 0.98 (95% CI 0.96–0.99) and 0.98 (95% CI 0.96–0.99), and the AUC were 0.98 (95% CI 0.97–0.99) and 0.99 (95% CI 0.97–0.99) in high TB burden and middle/low prevalence countries, respectively.ConclusionsThe diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance detection was excellent.